Combination of enzalutamide and in vivo cholesterol-conjugated RIG-I siRNA drugs targeting RACGAP1 induced potent inhibition of xenograft tumor growth of PCa. The gene discussed is RACGAP1; the disease is posterior cortical atrophy.